Accessibility Menu
Shield Therapeutics Plc logo

Shield Therapeutics Plc(LSE) STX

Market Cap£47.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-96%
5 Year-90%
1 Year-2%
1 Month-29%
£0.04
-7.27%
-0.00Today
Shield Therapeutics Plc last closing stock price
MetricPriceDate
Last closeGBX 4.402026-07-30
Shield Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-29.03%GBX 6.202026-07-23
1 month-29.03%GBX 6.202026-06-30
3 month-44.3%GBX 7.902026-05-01
Year to date-55.33%GBX 9.852025-12-31
1 year-2.22%GBX 4.502025-07-30
3 year-59.07%GBX 10.752023-07-31
5 year-89.77%GBX 43.002021-07-30
Since inception-96.12%GBX 1.482016-02-26

Shield Therapeutics Plc Financials at a Glance

Market Cap

£47.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$82.65M

Net Income (TTM)

-$45.08M

EPS (TTM)

-£0.01

P/E Ratio

-3.44

Dividend

£0.00

Beta (Volatility)

-0.14 (Low)

Price

£0.04

Volume

2,320,315

Open

£0.04

Previous Close

£0.04

Daily Range

£0.04 - £0.04

52-Week Range

£0.04 - £0.13

Estimated Earnings Date

Sep 3, 2026

STX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shield Therapeutics Plc

Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs. The company's lead product, Accrufer/Feraccru, is a non-salt based oral treatment for iron deficiency in adults, with or without anemia.

Products and Services
  • Accrufer/Feraccru: Oral therapy for iron deficiency
  • Focus on unmet medical needs in the pharmaceutical sector
  • Development of clinical-stage pharmaceuticals
Growth Outlook
  • Recent quarterly revenue reached $28.39 million, showing strong market demand
  • Continued investment in research and development to enhance product offerings
  • Expansion plans targeting new markets and patient demographics
Financial Highlights
  • Trailing twelve months revenue of $88.28 million, indicating growth potential
  • Gross profit margin improved to 44.16% in the latest quarter
  • Cash and cash equivalents stood at $11.63 million as of Q4 2025
Shield Therapeutics plc operates in the healthcare sector, specifically within the drug manufacturing industry, and is headquartered in Gateshead, United Kingdom. The company has a dedicated team of 61 employees and is committed to addressing significant health challenges through its innovative products. The financial performance reflects a focus on growth, with recent revenue trends indicating a positive trajectory. The company’s strategic initiatives aim to enhance its market presence and expand its product portfolio, making it an intriguing option for potential investors interested in the pharmaceutical sector.
AI Generated • Jul 12, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

Karl Anders Lundström

Website

www.shieldtherapeutics.com

Headquarters

Gateshead, GH NE8 3DF, GB

STX Financials

Key Financial Metrics (TTM)

Gross Margin

44.16%

Operating Margin

-20.44%

Net Income Margin

-35.72%

Return on Equity

121.87%

Return on Capital

-68.36%

Return on Assets

-27.96%

Earnings Yield

-29.07%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£47.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.07B

Volume

2.32M

Avg. Volume

2.17M

Financials (TTM)

Gross Profit

$37.19M

Operating Income

-$33.15M

EBITDA

-$30.11M

Operating Cash Flow

-$27.89M

Capital Expenditure

-$1.04M

Free Cash Flow

-$28.92M

Cash & ST Invst.

$11.63M

Total Debt

$30.15M

Shield Therapeutics Plc Performance Analysis

Shield Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,464,271193.9%
20232023-12-31USD 10,526,512135.8%
20242024-12-31USD 25,183,667139.2%
20252025-12-31USD 37,712,54849.8%
Shield Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Shield Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.1785.3%
20232023-12-31USD -0.04-78.6%
20242024-12-31USD -0.03-26.7%
20252025-12-31USD -0.01-52.9%
Shield Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$28.39M

+221.6%

Gross Profit

$12.10M

+874.6%

Gross Margin

42.63%

N/A

Market Cap

£47.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£771.46K

N/A

Employees

61

N/A

Net Income

-$8.16M

+60.9%

EBITDA

-$3.96M

+80.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$11.63M

-15.9%

Total Debt

$30.15M

+47.8%

Accounts Receivable

$24.39M

+119.3%

Inventory

$9.22M

+190.2%

Long Term Debt

$30.15M

+51.4%

Short Term Debt

$0.00

-100.0%

Return on Assets

-27.96%

N/A

Return on Invested Capital

-69.31%

N/A

Free Cash Flow

-$13.02M

+30.7%

Operating Cash Flow

-$13.00M

+25.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HEMO.LHemogenyx Pharmaceuticals Plc
£6.33-1.17%
BVC.LBATM Advanced Communications Ltd.
£0.13+4.18%
CREO.LCreo Medical Limited
£0.13-1.89%
EAH.LECO Animal Health Group plc
£0.98+1.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About STX

What is the current price of Shield Therapeutics Plc?

Shield Therapeutics Plc is trading at £0.04 per share.

What is the 52-week range for Shield Therapeutics Plc?

Over the past 52 weeks, Shield Therapeutics Plc has traded between £0.04 and £0.13.

How much debt does Shield Therapeutics Plc have?

As of the most recent reporting period, Shield Therapeutics Plc reported total debt of $22.40M.

How much cash does Shield Therapeutics Plc have on hand?

Shield Therapeutics Plc reported $8.64M in cash and cash equivalents in its most recent financial results.

What is Shield Therapeutics Plc’s dividend yield?

Shield Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services